Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The management team will conduct virtual investor meetings on December 2. A pre-recorded fireside chat presentation is available for streaming on Ocular Therapeutix's investor website, accessible for 90 days. The company focuses on innovative therapies for eye diseases, with FDA-approved DEXTENZA for ocular inflammation and ongoing clinical trials for treatments targeting glaucoma and dry eye disease.
- None.
- None.
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020.
In addition to a fireside chat, the management team will host virtual investor meetings on Wednesday, December 2nd at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Piper Sandler representative.
A webcast of the pre-recorded fireside chat presentation has been made available ahead of the conference and can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. It will be available for replay for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix recently completed a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension and OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases. Ocular Therapeutix is currently evaluating OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease in a Phase 2 clinical trial. Also, Ocular Therapeutix is currently developing OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease and, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to seal corneal incisions following cataract surgery.
